University of Maryland Researchers to Develop Devices to Revolutionize Drug Research
COLLEGE PARK, MD, September 18, 2007-A multi-disciplinary group of researchers from the University of Maryland, College Park, and the University of Maryland Biotechnology Institute (UMBI) has won a competitive, $2 million National Science Foundation (NSF) grant to revolutionize the way researchers develop and test pharmaceutical drugs.
The group, led by William Bentley, Herbert Rabin Distinguished Professor and chair of the Fischell Department of Bioengineering at the University of Maryland’s A. James Clark School of Engineering, plans to build devices that test new drugs using living, human biological components rather than “animal models,” thus significantly improving the accuracy and speed of drug development.
Currently, the average drug takes about 10 years and $1 billion in research dollars to reach the market.
“The current testing system, involving mice and other animals, doesn’t reflect the human body,” Bentley said. “This leads to inaccurate results that require additional rounds of testing, dragging out the process for years.”
Bentley and colleagues from UMBI, the Maryland NanoCenter, the Institute for Systems Research (ISR) and the Clark School’s electrical and computer engineering and materials science and engineering departments, are collaborating to build devices that will allow a drug researcher to input both a drug to be tested and specific human biological components, such as proteins or cells. Such adevice makes multiple, simultaneous measurements of how those components respond to the drug, to determine whether the drug is successful. The device thus serves as a research environment that mimics the human body.
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
New FDA Initiative Reveals Common Reasons for Drug Application Rejection
July 11th 2025By publishing more than 200 complete response letters, the FDA is offering new visibility into the issues that most often delay drug approvals, including safety concerns, trial design flaws, and manufacturing gaps.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.